Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pralatrexate

FDA-approved product (solution, intravenous), marketed as Folotyn, Pralatrexate.

Registered studies
44
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pralatrexate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Folic acid analogues
FDA pharmacologic class
Folate Analog Metabolic Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli82.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

44registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pralatrexate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pralatrexate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

    NCT01183065 · start 2010-08

    Registered record
    Registry ID
    NCT01183065
    Conditions
    Head and Neck Cancer
    Interventions
    Pralatrexate With Vitamin B12 and Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-08
    Completion
    2014-04
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionPralatrexate With Vitamin B12 and Folic Acid
    PhasePhase 2
    Registry statusCompleted

  • Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

    NCT01188876 · start 2010-08

    Registered record
    Registry ID
    NCT01188876
    Conditions
    Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
    Interventions
    carboplatin; pralatrexate; Folic Acid; Vitamin B12 Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2010-08
    Completion
    2017-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
    Interventioncarboplatin; pralatrexate; Folic Acid; Vitamin B12 Injection
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

    NCT01129206 · start 2010-07

    Registered record
    Registry ID
    NCT01129206
    Conditions
    Adenocarcinoma of the Esophagus; Adenocarcinomas of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus; Stage IV Esophageal Cancer
    Interventions
    pralatrexate; docetaxel; fludeoxyglucose F 18; positron emission tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07
    Completion
    Not recorded
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Esophagus; Adenocarcinomas of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus +1 more
    Interventionpralatrexate; docetaxel; fludeoxyglucose F 18; positron emission tomography
    PhasePhase 2
    Registry statusCompleted

  • Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

    NCT01118624 · start 2010-03

    Registered record
    Registry ID
    NCT01118624
    Conditions
    Breast Cancer; Breast Tumors; Neoplasms, Breast; Cancer of the Breast; Human Mammary Carcinoma
    Interventions
    Pralatrexate Injection; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-07
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Tumors; Neoplasms, Breast; Cancer of the Breast +1 more
    InterventionPralatrexate Injection; Vitamin B12; Folic Acid
    PhasePhase 2
    Registry statusCompleted

  • Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

    NCT01134341 · start 2010-03

    Registered record
    Registry ID
    NCT01134341
    Conditions
    Cutaneous T-cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Primary Cutaneous Anaplastic Large Cell Lymphoma
    Interventions
    Pralatrexate Injection; Bexarotene Capsules; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2015-08
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T-cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Primary Cutaneous Anaplastic Large Cell Lymphoma
    InterventionPralatrexate Injection; Bexarotene Capsules; Vitamin B12; Folic Acid
    PhasePhase 1
    Registry statusCompleted

  • Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

    NCT00998946 · start 2009-09

    Registered record
    Registry ID
    NCT00998946
    Conditions
    Lymphoma, B-Cell
    Interventions
    Pralatrexate; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2012-08
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, B-Cell
    InterventionPralatrexate; Vitamin B12; Folic Acid
    PhasePhase 2
    Registry statusCompleted

  • Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

    NCT00722553 · start 2008-07

    Registered record
    Registry ID
    NCT00722553
    Conditions
    Carcinoma, Transitional Cell; Bladder Cancer; Bladder Neoplasm
    Interventions
    Pralatrexate Injection; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Transitional Cell; Bladder Cancer; Bladder Neoplasm
    InterventionPralatrexate Injection; Vitamin B12; Folic Acid
    PhasePhase 2
    Registry statusCompleted

  • Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

    NCT00606502 · start 2008-01

    Registered record
    Registry ID
    NCT00606502
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Pralatrexate; Erlotinib; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-06-24
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionPralatrexate; Erlotinib; Vitamin B12; Folic Acid
    PhasePhase 2
    Registry statusCompleted

  • Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

    NCT00554827 · start 2007-08

    Registered record
    Registry ID
    NCT00554827
    Conditions
    Cutaneous T-cell Lymphoma
    Interventions
    Vitamin B12; Folic Acid; Pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-08
    Completion
    2012-02
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T-cell Lymphoma
    InterventionVitamin B12; Folic Acid; Pralatrexate
    PhasePhase 1
    Registry statusCompleted

  • Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

    NCT00481871 · start 2007-05

    Registered record
    Registry ID
    NCT00481871
    Conditions
    Relapsed or Refractory Lymphoproliferative Malignancies; Hodgkin's Lymphoma; Peripheral T-cell Lymphoma; B-cell Lymphoma; Waldenstrom's Macroglobulinemia
    Interventions
    Pralatrexate Injection; Gemcitabine Hydrochloride; Vitamin B12; Folic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2011-08
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Lymphoproliferative Malignancies; Hodgkin's Lymphoma; Peripheral T-cell Lymphoma; B-cell Lymphoma +1 more
    InterventionPralatrexate Injection; Gemcitabine Hydrochloride; Vitamin B12; Folic Acid
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

    NCT00364923 · start 2006-08

    Registered record
    Registry ID
    NCT00364923
    Conditions
    Peripheral T-cell Lymphoma
    Interventions
    Pralatrexate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2009-02-24
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T-cell Lymphoma
    InterventionPralatrexate Injection
    PhasePhase 2
    Registry statusCompleted

  • 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

    NCT00052442 · start 2002-08

    Registered record
    Registry ID
    NCT00052442
    Conditions
    Lymphoma
    Interventions
    pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2002-08
    Completion
    2009-03
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionpralatrexate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors

    NCT00024245 · start 2001-05

    Registered record
    Registry ID
    NCT00024245
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    pralatrexate; probenecid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-05
    Completion
    2003-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionpralatrexate; probenecid
    PhasePhase 1
    Registry statusCompleted

  • 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

    NCT00004238 · start 1999-07

    Registered record
    Registry ID
    NCT00004238
    Conditions
    Lung Cancer
    Interventions
    pralatrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-07
    Completion
    2002-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventionpralatrexate
    PhasePhase 2
    Registry statusCompleted